Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ferguson, J.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ferguson, J.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Antithrombin therapy, antiplatelet therapy and percutaneous coronary intervention: rationale and design of the SYNERGY trial

J.J. Ferguson*

Texas Heart Institute, Houston, Texas, USA

* Correspondence: James J. Ferguson, MD, Associate Director, Cardiology Research, Texas Heart Institute, St. Luke's Episcopal Hospital, 6720 Benner Avenue, Mail Code 1-191, Houston, TX 77030, USA

Abstract

Although low-molecular-weight heparins (LMWHs) have been shown to be equivalent or superior to unfractionated heparin for the management of patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI), a number of clinical issues remain. Among them are the safety of bringing patients to the catheterization laboratory and the use of glycoprotein (GP)Ilb/Illa antagonists. The Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors (SYNERGY) trial is a randomized study comparing the safety and efficacy of unfractionated heparin and the LMWH enoxaparin in high-risk, invasively managed UA/NSTEMI patients who are likely to receive GPIIb/IIIa antagonists.

Key Words: Heparin • low-molecular-weight heparin • percutaneous atherectomy • platelet glycoprotein IIb/IIIa receptor antagonist/inhibitor • unstable angina

References

  1. Granger C, Lopez-Sendon J, Werf FVd, et al. Applying the evidence in acute coronary syndromes: a report card from the global registry of acute coronary events [abstract]. J Am Coll Cardiol. 2001;37:503A
  2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326:310–318[Web of Science][Medline]
  3. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811–815[Abstract/Free Full Text]
  4. Wallentin L. Low molecular weight heparin in unstable coronary artery disease. Expert Opin Investig Drugs. 2000;9:581–592[CrossRef][Web of Science][Medline]
  5. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608[Abstract/Free Full Text]
  6. AnonymousLancet. 1996;347:561–568[CrossRef][Web of Science][Medline]
  7. Klein W, Buchwald A, Hillis SE, et al. Comparison of lowmolecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease study (ERIC). Circulation. 1997;96:61–68[Abstract/Free Full Text]
  8. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) I1B trial. Circulation. 1999;100:1593–1601[Abstract/Free Full Text]
  9. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events study group. N Engl J Med. 1997;337:447–452[Abstract/Free Full Text]
  10. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events. J Am Coll Cardiol. 2000;36:693–698[Abstract/Free Full Text]
  11. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered sub cutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995;73:630–640[Web of Science][Medline]
  12. AnonymousEur Heart J. 1999;20:1553–1562[Abstract/Free Full Text]
  13. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative manage ment strategy. Veterans Affairs Non-Q-wave Infarction Strategies in Hospital (VANQWISH) trial investigators. N Engl J Med. 1998;338:1785–1792[Abstract/Free Full Text]
  14. AnonymousLancet. 1999;354:708–715[CrossRef][Web of Science][Medline]
  15. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutancous coronary intervention in stable angina pectoris. Am J Cardiol. 1999;84:1391–1395[CrossRef][Web of Science][Medline]
  16. Diez JG, Lievano MJ, Croitoru M, Olay CA, Ferguson JJ. Enoxaparin anticoagulation for percutancous coronary interventions: a pilot safety study [abstract]. Circulation. 1999;100:I–188
  17. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658–663[Abstract/Free Full Text]
  18. Cohen M, Theroux P, Frey MJ, et al. Anti-thrombotic Combination using Tirofiban and Enoxaparin: the ACUTE 11 study [abstract]. Circulation. 2000;102:II–826
  19. Simoons ML. Effect of glycoprotein iib/iiia receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915–1924[CrossRef][Web of Science][Medline]
  20. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001;13:272–278[Medline]
  21. AnonymousLancet. 1998;352:87–92[Web of Science][Medline]
  22. AnonymousN Engl J Med. 1997;336:1689–1696[Abstract/Free Full Text]
  23. Ferguson JJ. Combining low-molecular-weight heparin and glycoprotein IIb/Ilia antagonists for the treatment of acute coronary syndromes: The NICE 3 story. National Investigators Collaborating on Enoxaparin. J Invasive Cardiol. 2000;12(suppl E):E10–E13 discussion E25-8
  24. Ferguson JJ, Antman EM, Bates ER, et al. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study [abstract]. J Am Coll Cardiol. 2001;37(suppl A):365A

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ferguson, J.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ferguson, J.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?